The DYNC1I1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-engineered polyclonal population of human HAP1 cells with targeted disruption of the DYNC1I1 gene, encoding cytoplasmic dynein intermediate chain 1. This knockout model facilitates investigation of dynein-mediated retrograde transport and mitotic regulation in a near-haploid background. The polyclonal format preserves population-level genetic diversity while enabling loss-of-function studies, providing a renewable resource for interrogating cytoplasmic dynein function without clonal artifacts.
HAP1 cells are a near-haploid human male line derived from the KBM-7 chronic myeloid leukemia (CML) isolate, widely employed for CRISPR-Cas9 screening. They exhibit adherent fibroblast-like morphology and can be adapted for suspension culture, offering experimental versatility. Their near-haploid karyotype simplifies genetic analysis and phenotypic interpretation.
DYNC1I1 is a core component of the cytoplasmic dynein motor complex, bridging cargo and regulatory adaptors. It directly binds the heavy chain DYNC1H1 and interacts with the dynactin subunit DCTN1, while it is regulated by dynein-activating adaptors BICD2 and HOOK3, the cofactors LIS1 and NDEL1, and CDK1-mediated phosphorylation. The complex carries mitochondria, endosomes, lysosomes, and Golgi vesicles toward microtubule minus ends. Disruption of DYNC1I1 impairs these trafficking processes and compromises mitotic spindle assembly, partly through mislocalization of the checkpoint protein MAD2.
In the HAP1 context, loss of DYNC1I1 creates a robust model of dynein insufficiency relevant to leukemia biology and neurodevelopmental diseases such as spinal muscular atrophy. The near-haploid state accelerates phenotype manifestation, enabling clear readouts in proliferation and migration. This system is particularly suited for studying mitotic fidelity, chromosomal instability, and chemosensitivity in CML, and supports investigations into dynein-dependent processes in both hematopoietic and neural contexts.
Researchers can employ these polyclonal knockout cells for Western blot confirmation of protein depletion, immunofluorescence-based analysis of mitotic spindle morphology, and live-cell imaging to track defects in vesicle and mitochondrial motility. Flow cytometry quantifies cell cycle perturbations, while migration and invasion assays assess metastatic potential. Drug sensitivity profiling with dynein inhibitors or taxanes adds pharmacological value. For further technical information or custom requests, contact Ascent Research.
